About Trident Lifeline Limited
Data last updated:
Trident Lifeline Limited is a public limited company based in Surat, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 09 January 2014 and has been in existence for over 12 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L51909GJ2014PLC078227. Its GSTIN is 24AAECT8906D1ZG (Gujarat). It is a listed company.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹11.93 Cr. It is led by directors including Shravan H Patel (Managing Director) and Rupaben Chetan Jariwala (Whole-Time Director).
Its last annual general meeting (AGM) was held on 27 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 2nd Floor Shop – 2004 North Extension Falsawadi Begumpura Nodh – 4/1650 Sahara Darwaja, Surat, Gujarat, India – 395003.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹129.02 Cr, a growth of 48.4% compared to the previous year. For the same year it recorded a net profit of ₹19.03 Cr (net margin 14.7%) and EBITDA of ₹28.11 Cr (EBITDA margin 21.8%). The net worth stands at ₹100.4 Cr (up 55.8% YoY). Total assets are valued at ₹180.95 Cr (up 46.2% YoY).
The company has about 27 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Trident Lifeline. As per MCA filings, the company has open charges of ₹132.81 Cr and satisfied charges of ₹1.58 Cr on record. Court records list 1 case involving the company; 1 case is pending. The company has 19 deals on record (13 secondary share transfers, 4 funding rounds, 1 rights issue), with disclosed funding of ₹6.79 Cr; the latest was in October 2022. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Linux Life Sciences Private Limited. The company has 13 MSME Form 1 returns on record between 2019 and 2023, listing 435 overdue payments to 43 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website tridentlifeline.com.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered Address2nd Floor Shop – 2004 North Extension Falsawadi Begumpura Nodh – 4/1650 Sahara Darwaja, Surat, Gujarat, India – 395003
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Trident Lifeline Limited
The main business activity of Trident Lifeline is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Trident Lifeline Limited FY 2025-26 filings available
Trident Lifeline Limited reported revenue of ₹129.02 Cr (up 48.4% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 129 | 86.96 | 44.63 | 31.69 | 21.77 |
| Revenue growth | +48.4% | +94.9% | +40.8% | +45.6% | - |
| EBITDA | 28.11 | 15.00 | 8.23 | 6.26 | 2.71 |
| EBITDA margin | +21.8% | +17.3% | +18.4% | +19.8% | +12.5% |
| Profit before tax | 27.19 | 13.60 | 8.69 | 6.58 | 2.98 |
| Net profit | 19.03 | 11.73 | 6.33 | 6.02 | 3.94 |
| Net profit margin | +14.8% | +13.5% | +14.2% | +19.0% | +18.1% |
| EPS (₹) | 16.32 | 10.22 | 5.52 | 5.23 | 4.93 |
| Balance sheet | |||||
| Total assets | 181 | 124 | 72.43 | 54.87 | 7.30 |
| Net worth | 100 | 64.46 | 52.90 | 45.64 | 4.78 |
| Total debt | 72.99 | 54.03 | 18.41 | 7.69 | 2.46 |
| Cash & bank | 4.22 | 2.46 | 6.65 | 13.78 | 0.16 |
| Net working capital | 84.56 | 58.58 | 37.32 | 41.51 | 4.13 |
| Cash flow | |||||
| Cash from operations | 4.69 | (3.98) | 2.23 | (19.00) | (0.21) |
| Cash from investing | (36.61) | (13.71) | (20.36) | (9.69) | (0.45) |
| Cash from financing | 33.68 | 13.50 | 11.01 | 42.28 | 0.80 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 33.72 | 49.95 | 25.71 | 31.34 | 23.61 | 34.01 | 11.83 | 15.45 |
| Revenue growth (YoY) | +42.8% | +46.9% | +117.3% | +102.9% | +79.5% | - | - | - |
| Other income | 0.57 | 1.62 | 4.63 | 1.67 | 1.35 | 1.87 | 0.56 | 0.54 |
| EBITDA | 8.52 | 10.98 | 5.09 | 6.86 | 5.17 | 8.53 | 4.08 | 4.05 |
| EBITDA margin | +25.3% | +22.0% | +19.8% | +21.9% | +21.9% | +25.1% | +34.5% | +26.2% |
| Depreciation | 1.62 | 1.23 | 2.46 | 0.91 | 1.46 | 2.74 | 0.61 | 0.16 |
| Interest | 0.86 | 0.77 | 1.24 | 0.99 | 1.13 | 1.55 | 0.55 | 0.50 |
| Profit before tax | 6.61 | 10.60 | 6.02 | 6.63 | 3.93 | 6.11 | 3.48 | 3.93 |
| Tax | 1.54 | 3.82 | 1.37 | 1.54 | 1.15 | (0.02) | 0.92 | 1.12 |
| Net profit | 5.07 | 6.78 | 4.65 | 5.09 | 2.78 | 6.13 | 2.56 | 2.81 |
| EPS (₹) | 4.27 | 5.76 | 3.72 | 4.27 | 2.66 | 6.15 | 2.42 | 2.69 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 102 | 67.80 | 44.65 | 31.69 | 21.77 | 9.62 | 4.93 |
| Revenue growth | +50.3% | +51.9% | +40.9% | +45.6% | +126.3% | +95.1% | - |
| EBITDA | 24.33 | 17.66 | 8.87 | 6.26 | 2.71 | 1.26 | (0.28) |
| EBITDA margin | +23.9% | +26.1% | +19.9% | +19.8% | +12.5% | +13.1% | -5.7% |
| Profit before tax | 24.98 | 17.89 | 9.79 | 6.57 | 2.98 | 0.87 | (1.09) |
| Net profit | 18.09 | 13.04 | 7.03 | 6.01 | 3.94 | 0.65 | (0.82) |
| Net profit margin | +17.8% | +19.2% | +15.7% | +19.0% | +18.1% | +6.8% | -16.6% |
| EPS (₹) | 15.50 | 11.35 | 6.13 | 5.23 | 4.93 | 1.26 | (2.57) |
| Balance sheet | |||||||
| Total assets | 124 | 80.69 | 58.94 | 49.08 | 7.30 | 4.11 | 3.52 |
| Net worth | 99.09 | 65.73 | 52.68 | 45.63 | 4.78 | (0.47) | (3.00) |
| Total debt | 24.60 | 14.89 | 6.20 | 3.38 | 2.46 | 4.53 | 6.46 |
| Cash & bank | 4.07 | 2.11 | 6.01 | 13.77 | 0.13 | 0.09 | 0.12 |
| Net working capital | 75.54 | 52.49 | 38.69 | 40.44 | 4.11 | 0.40 | (0.05) |
| Cash flow | |||||||
| Cash from operations | 7.93 | 1.97 | 0.90 | (16.60) | (0.19) | 1.48 | (0.59) |
| Cash from investing | (20.07) | (7.88) | (11.01) | (5.56) | (0.50) | (0.56) | (0.08) |
| Cash from financing | 14.10 | 2.01 | 2.35 | 35.80 | 0.80 | (0.96) | 0.76 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.84 | 31.97 | 23.67 | 27.44 | 18.82 | 20.85 | 16.51 | 15.66 |
| Revenue growth (YoY) | +42.6% | +53.3% | +43.4% | +75.2% | +27.7% | - | - | - |
| Other income | 0.53 | 1.64 | 0.89 | 1.11 | 0.54 | 1.61 | 0.54 | 0.52 |
| Total expenses | 19.62 | 25.23 | 17.39 | 21.06 | 13.89 | 15.27 | 12.37 | 11.24 |
| EBITDA | 7.22 | 6.74 | 6.28 | 6.38 | 4.93 | 5.58 | 4.14 | 4.42 |
| EBITDA margin | +26.9% | +21.1% | +26.5% | +23.3% | +26.2% | +26.8% | +25.1% | +28.2% |
| Depreciation | 0.70 | 0.04 | 0.71 | 0.59 | 0.51 | 0.71 | 0.38 | 0.16 |
| Interest | 0.49 | 0.38 | 0.54 | 0.42 | 0.33 | 0.46 | 0.35 | 0.27 |
| Profit before tax | 6.56 | 7.96 | 5.92 | 6.48 | 4.63 | 6.02 | 3.95 | 4.51 |
| Tax | 1.54 | 2.29 | 1.91 | 1.54 | 1.15 | 1.66 | 0.92 | 1.12 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 33.72 | 49.95 | 25.71 | 31.34 | 23.61 | 34.01 | 11.83 | 15.45 |
| Revenue growth (YoY) | +42.8% | +46.9% | +117.3% | +102.9% | +79.5% | - | - | - |
| Other income | 0.57 | 1.62 | 4.63 | 1.67 | 1.35 | 1.87 | 0.56 | 0.54 |
| EBITDA | 8.52 | 10.98 | 5.09 | 6.86 | 5.17 | 8.53 | 4.08 | 4.05 |
| EBITDA margin | +25.3% | +22.0% | +19.8% | +21.9% | +21.9% | +25.1% | +34.5% | +26.2% |
| Depreciation | 1.62 | 1.23 | 2.46 | 0.91 | 1.46 | 2.74 | 0.61 | 0.16 |
| Interest | 0.86 | 0.77 | 1.24 | 0.99 | 1.13 | 1.55 | 0.55 | 0.50 |
| Profit before tax | 6.61 | 10.60 | 6.02 | 6.63 | 3.93 | 6.11 | 3.48 | 3.93 |
| Tax | 1.54 | 3.82 | 1.37 | 1.54 | 1.15 | (0.02) | 0.92 | 1.12 |
| Net profit | 5.07 | 6.78 | 4.65 | 5.09 | 2.78 | 6.13 | 2.56 | 2.81 |
| EPS (₹) | 4.27 | 5.76 | 3.72 | 4.27 | 2.66 | 6.15 | 2.42 | 2.69 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Revenue | 129 | 86.96 | 44.63 | 31.69 | 21.77 |
| Revenue growth | +48.4% | +94.9% | +40.8% | +45.6% | - |
| Other income | 9.27 | 8.23 | 2.08 | 1.16 | 0.60 |
| Total expenses | 101 | 71.96 | 36.40 | 25.43 | 19.06 |
| Employee cost | 0.00 | 10.89 | 2.29 | 1.39 | 1.10 |
| EBITDA | 28.11 | 15.00 | 8.23 | 6.26 | 2.71 |
| EBITDA margin | +21.8% | +17.3% | +18.4% | +19.8% | +12.5% |
| Depreciation | 6.07 | 5.49 | 0.97 | 0.36 | 0.20 |
| Interest | 4.12 | 4.14 | 0.65 | 0.48 | 0.13 |
| Profit before tax | 27.19 | 13.60 | 8.69 | 6.58 | 2.98 |
| Tax | 7.88 | 3.12 | 2.75 | 0.56 | (0.96) |
| Net profit | 19.03 | 11.73 | 6.33 | 6.02 | 3.94 |
| Net profit margin | +14.8% | +13.5% | +14.2% | +19.0% | +18.1% |
| EPS (₹) | 16.32 | 10.22 | 5.52 | 5.23 | 4.93 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Equity & liabilities | |||||
| Share capital | 11.93 | 11.50 | 11.50 | 11.50 | 8.00 |
| Reserves & surplus | 84.74 | 52.96 | 40.41 | 34.14 | (3.22) |
| Shareholders' funds (net worth) | 100 | 64.46 | 52.90 | 45.64 | 4.78 |
| Minority interest | 7.49 | 5.19 | 1.05 | 1.47 | 0.00 |
| Secured loans | 56.65 | 41.15 | 14.42 | 6.20 | 0.60 |
| Unsecured loans | 16.34 | 12.88 | 3.99 | 1.49 | 1.86 |
| Total debt | 72.99 | 54.03 | 18.41 | 7.69 | 2.46 |
| Total liabilities | 181 | 124 | 72.43 | 54.87 | 7.30 |
| Assets | |||||
| Gross block | 78.30 | 57.40 | 23.03 | 4.33 | 2.23 |
| Net block | 60.70 | 43.87 | 20.89 | 3.16 | 1.43 |
| Capital work in progress | 17.54 | 1.60 | 4.03 | 4.83 | 0.00 |
| Investments | 8.27 | 10.72 | 3.77 | 3.34 | 0.00 |
| Inventories | 36.44 | 28.24 | 12.58 | 7.17 | 3.71 |
| Sundry debtors | 73.65 | 27.68 | 13.44 | 12.09 | 4.97 |
| Cash & bank balances | 4.22 | 2.46 | 6.65 | 13.78 | 0.16 |
| Loans & advances | 25.18 | 31.99 | 19.29 | 16.17 | 1.83 |
| Total current assets | 139 | 90.37 | 51.96 | 49.21 | 10.67 |
| Total current liabilities | 54.93 | 31.79 | 14.64 | 7.70 | 6.54 |
| Net working capital | 84.56 | 58.58 | 37.32 | 41.51 | 4.13 |
| Total assets | 181 | 124 | 72.43 | 54.87 | 7.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Opening cash | 2.46 | 6.65 | 13.78 | 0.18 | 0.01 |
| Net cash from operating activities | 4.69 | (3.98) | 2.23 | (19.00) | (0.21) |
| Net cash from investing activities | (36.61) | (13.71) | (20.36) | (9.69) | (0.45) |
| Net cash from financing activities | 33.68 | 13.50 | 11.01 | 42.28 | 0.80 |
| Net change in cash | 1.76 | (4.19) | (7.13) | 13.60 | 0.14 |
| Closing cash | 4.22 | 2.46 | 6.65 | 13.78 | 0.16 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Growth | |||||
| Sales growth | +48.4% | +94.9% | +40.8% | +45.6% | - |
| EBITDA growth | +87.4% | +82.3% | +31.5% | +131.0% | - |
| PBT growth | +99.9% | +56.5% | +32.1% | +120.8% | +9997.0% |
| Net income growth | +62.2% | +85.3% | +5.2% | +52.8% | - |
| Revenue CAGR (3Y) | +59.7% | +58.7% | - | - | - |
| EBITDA CAGR (3Y) | +65.0% | +76.9% | - | - | - |
| Profitability & leverage | |||||
| Net income margin | +15.0% | +12.1% | +13.3% | +19.0% | +18.1% |
| Return on capital employed | - | +18.7% | +15.0% | +22.1% | +29.7% |
| Return on net worth | - | +17.9% | +12.1% | +22.4% | +49.4% |
| Debt / equity | - | 0.62 | 0.26 | 0.20 | 0.51 |
| Long-term debt / equity | - | 0.38 | 0.17 | 0.10 | 0.30 |
| Interest cover | 18.69 | 43.53 | 8.95 | 8.14 | 5.18 |
| Efficiency & per share | |||||
| Fixed asset turnover | - | 2.16 | 3.26 | 9.66 | 9.76 |
| Inventory turnover | - | 4.26 | 4.52 | 5.83 | 5.87 |
| Debtors turnover | - | 4.23 | 3.50 | 3.72 | 4.38 |
| EPS (₹) | 16.32 | 10.22 | 5.52 | 5.23 | 4.93 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 56.05 | 45.14 | 39.69 | 5.97 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.84 | 31.97 | 23.67 | 27.44 | 18.82 | 20.85 | 16.51 | 15.66 |
| Revenue growth (YoY) | +42.6% | +53.3% | +43.4% | +75.2% | +27.7% | - | - | - |
| Other income | 0.53 | 1.64 | 0.89 | 1.11 | 0.54 | 1.61 | 0.54 | 0.52 |
| Total expenses | 19.62 | 25.23 | 17.39 | 21.06 | 13.89 | 15.27 | 12.37 | 11.24 |
| EBITDA | 7.22 | 6.74 | 6.28 | 6.38 | 4.93 | 5.58 | 4.14 | 4.42 |
| EBITDA margin | +26.9% | +21.1% | +26.5% | +23.3% | +26.2% | +26.8% | +25.1% | +28.2% |
| Depreciation | 0.70 | 0.04 | 0.71 | 0.59 | 0.51 | 0.71 | 0.38 | 0.16 |
| Interest | 0.49 | 0.38 | 0.54 | 0.42 | 0.33 | 0.46 | 0.35 | 0.27 |
| Profit before tax | 6.56 | 7.96 | 5.92 | 6.48 | 4.63 | 6.02 | 3.95 | 4.51 |
| Tax | 1.54 | 2.29 | 1.91 | 1.54 | 1.15 | 1.66 | 0.92 | 1.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 102 | 67.80 | 44.65 | 31.69 | 21.77 | 9.62 | 4.93 |
| Revenue growth | +50.3% | +51.9% | +40.9% | +45.6% | +126.3% | +95.1% | - |
| Other income | 4.17 | 3.14 | 2.20 | 1.15 | 0.60 | 0.16 | 0.07 |
| Total expenses | 77.57 | 50.14 | 35.78 | 25.43 | 19.06 | 8.36 | 5.21 |
| Employee cost | 0.00 | 2.51 | 1.55 | 1.39 | 1.10 | 0.70 | 0.71 |
| EBITDA | 24.33 | 17.66 | 8.87 | 6.26 | 2.71 | 1.26 | (0.28) |
| EBITDA margin | +23.9% | +26.1% | +19.9% | +19.8% | +12.5% | +13.1% | -5.7% |
| Depreciation | 1.86 | 1.53 | 0.77 | 0.36 | 0.20 | 0.14 | 0.12 |
| Interest | 1.66 | 1.38 | 0.51 | 0.48 | 0.13 | 0.41 | 0.76 |
| Profit before tax | 24.98 | 17.89 | 9.79 | 6.57 | 2.98 | 0.87 | (1.09) |
| Tax | 6.89 | 4.85 | 2.75 | 0.56 | (0.96) | 0.22 | (0.28) |
| Net profit | 18.09 | 13.04 | 7.03 | 6.01 | 3.94 | 0.65 | (0.82) |
| Net profit margin | +17.8% | +19.2% | +15.7% | +19.0% | +18.1% | +6.8% | -16.6% |
| EPS (₹) | 15.50 | 11.35 | 6.13 | 5.23 | 4.93 | 1.26 | (2.57) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.93 | 11.50 | 11.50 | 11.50 | 8.00 | 5.00 | 3.10 |
| Reserves & surplus | 83.43 | 54.23 | 41.18 | 34.13 | (3.22) | (5.47) | (6.10) |
| Shareholders' funds (net worth) | 99.09 | 65.73 | 52.68 | 45.63 | 4.78 | (0.47) | (3.00) |
| Secured loans | 21.20 | 13.02 | 6.20 | 2.73 | 0.60 | 0.00 | 0.00 |
| Unsecured loans | 3.40 | 1.87 | 0.00 | 0.65 | 1.86 | 4.53 | 6.46 |
| Total debt | 24.60 | 14.89 | 6.20 | 3.38 | 2.46 | 4.53 | 6.46 |
| Total liabilities | 124 | 80.69 | 58.94 | 49.08 | 7.30 | 4.11 | 3.52 |
| Assets | |||||||
| Gross block | 33.91 | 18.26 | 9.55 | 4.27 | 2.23 | 1.77 | 1.22 |
| Net block | 28.59 | 14.80 | 7.62 | 3.11 | 1.43 | 1.18 | 0.77 |
| Capital work in progress | 0.00 | 0.54 | 4.03 | 0.23 | 0.00 | 0.00 | 0.00 |
| Investments | 19.74 | 12.49 | 4.40 | 4.04 | 0.05 | 0.00 | 0.00 |
| Inventories | 23.22 | 16.57 | 11.06 | 7.17 | 3.71 | 5.27 | 0.94 |
| Sundry debtors | 49.34 | 20.40 | 13.76 | 12.15 | 4.97 | 0.64 | 1.31 |
| Cash & bank balances | 4.07 | 2.11 | 6.01 | 13.77 | 0.13 | 0.09 | 0.12 |
| Loans & advances | 33.41 | 30.05 | 22.15 | 14.77 | 1.83 | 1.74 | 0.45 |
| Total current assets | 110 | 69.13 | 52.98 | 47.86 | 10.64 | 7.74 | 2.82 |
| Total current liabilities | 34.50 | 16.64 | 14.29 | 7.42 | 6.53 | 7.34 | 2.87 |
| Net working capital | 75.54 | 52.49 | 38.69 | 40.44 | 4.11 | 0.40 | (0.05) |
| Total assets | 124 | 80.69 | 58.94 | 49.08 | 7.30 | 4.11 | 3.52 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.11 | 6.01 | 13.77 | 0.13 | 0.01 | 0.12 | 0.04 |
| Net cash from operating activities | 7.93 | 1.97 | 0.90 | (16.60) | (0.19) | 1.48 | (0.59) |
| Net cash from investing activities | (20.07) | (7.88) | (11.01) | (5.56) | (0.50) | (0.56) | (0.08) |
| Net cash from financing activities | 14.10 | 2.01 | 2.35 | 35.80 | 0.80 | (0.96) | 0.76 |
| Net change in cash | 1.96 | (3.90) | (7.76) | 13.64 | 0.11 | (0.03) | 0.08 |
| Closing cash | 4.07 | 2.11 | 6.01 | 13.77 | 0.13 | 0.09 | 0.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +50.3% | +51.9% | +40.9% | +45.6% | +126.3% | +95.1% | - |
| EBITDA growth | +37.8% | +99.1% | +41.7% | +131.0% | +115.1% | +550.0% | - |
| PBT growth | +39.6% | +82.7% | +49.0% | +120.5% | +242.5% | +9998.0% | +9997.0% |
| Net income growth | +38.7% | +85.5% | +17.0% | +52.5% | +506.2% | +179.3% | - |
| Revenue CAGR (3Y) | +47.6% | +46.0% | +66.8% | +85.9% | - | - | - |
| EBITDA CAGR (3Y) | +57.2% | +86.8% | +91.7% | - | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +17.8% | +19.2% | +15.8% | +19.0% | +18.1% | +6.8% | -16.4% |
| Return on capital employed | - | +27.6% | +19.1% | +23.7% | +31.0% | +19.2% | 0.0% |
| Return on net worth | - | +22.0% | +14.3% | +22.4% | +60.8% | +63.0% | 0.0% |
| Debt / equity | - | 0.18 | 0.10 | 0.12 | 1.62 | 0.00 | 0.00 |
| Long-term debt / equity | - | 0.08 | 0.04 | 0.04 | 1.36 | 0.00 | 0.00 |
| Interest cover | 7.39 | 8.56 | 6.30 | 8.14 | 5.18 | 36.61 | -190.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 4.88 | 6.46 | 9.75 | 10.89 | 6.43 | 4.04 |
| Inventory turnover | - | 4.91 | 4.90 | 5.83 | 4.85 | 3.10 | 5.24 |
| Debtors turnover | - | 3.97 | 3.45 | 3.70 | 7.76 | 9.87 | 3.76 |
| EPS (₹) | 15.50 | 11.35 | 6.13 | 5.23 | 4.93 | 1.26 | (2.57) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 57.16 | 45.81 | 39.68 | 5.97 | (0.94) | (9.69) |
Peer Comparison of Trident Lifeline Limited
Trident Lifeline Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Revenue, net profit, margin and growth of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Trident Lifeline Limited this company | •••• | •••• | •••• | •••• | - | Surat, Gujarat, India |
| Linux Life Sciences Private Limited | •••• | •••• | •••• | •••• | 107 | Pondicherry, India |
| Lozen Pharma Private Limited | •••• | •••• | •••• | •••• | 139 | Savanur, Karnataka, India |
| Sanctus Global Formulations Limited | •••• | •••• | •••• | •••• | 136 | Chandigarh, India |
| Navyug Pharma- Chem Pvt. Ltd. | •••• | •••• | •••• | •••• | - | Gujarat, India |
| Quantime World Private Limited | •••• | •••• | •••• | •••• | 23 | Pune, Maharashtra, India |
| Reliance Formulation Pvt Ltd | •••• | •••• | •••• | •••• | 215 | Ahmedabad, Gujarat, India |
| Abhideep Chemicals Pvt Ltd | •••• | •••• | •••• | •••• | 92 | Mumbai, Maharashtra, India |
| Gufic Lifesciences Private Limited | •••• | •••• | •••• | •••• | - | Navsari, Gujarat, India |
| Amn Life Private Limited | •••• | •••• | •••• | •••• | 331 | Mumbai, Maharashtra, India |
| Chemic Life Sciences Private Limited | •••• | •••• | •••• | •••• | 68 | Hyd, Telangana, India |
Peers are the five companies nearest above and the five nearest below Trident Lifeline by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Revenue, net profit, margin and growth of each peer are in the company report.
Auditor Details of Trident Lifeline Limited
Trident Lifeline Limited is audited by A Bafna & Associates for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| A Bafna & Associates | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Trident Lifeline Limited
Trident Lifeline has 8 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Hardik Jigishkumar Desai | Director | 27 Jun 2022 | 4 Years 3 Months | Current |
| Shravan H Patel | Managing Director | 04 Jul 2022 | 4 Years 3 Months | Current |
| Ashish Anandsingh Bafna Also directs: TLL Ventures Private Limited | Director | 01 Sep 2025 | 1 Years 1 Months | Current |
| Rupaben Chetan Jariwala Also directs: VN Capital Services LLP, TLL Elements Private Limited | Whole-Time Director | 16 May 2024 | 2 Years 4 Months | Current |
| Falguni Bhavesh Jariwala | Director | 27 Apr 2024 | 2 Years 5 Months | Current |
| Mishal Shailesh Patel Also directs: Trident Texofab Limited | Director | 22 Jul 2023 | 3 Years 2 Months | Current |
Shareholding Pattern of Trident Lifeline Limited
Shareholding for the quarter ended Sep 2026: promoters hold 62.60%, foreign institutional investors hold 5.20%, domestic institutional investors hold 0.30% and retail and other public shareholders hold 31.90%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 62.60% | 62.80% | 64.10% | 63.10% |
| Public | 37.40% | 37.20% | 35.90% | 36.90% |
Charges & Borrowings of Trident Lifeline Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Jun 2026 | Others | ₹15 Cr | Open |
| 12 Jun 2026 | Others | ₹15 Cr | Open |
| 03 Nov 2025 | Others | ₹39.98 Lakh | Open |
| 27 Apr 2025 | Yes Bank Limited | ₹5 Cr | Open |
| 01 Mar 2025 | Yes Bank Limited | ₹2.5 Cr | Open |
Total charge records: 17 View all charges
Deals & Funding of Trident Lifeline Limited
Trident Lifeline Limited has 19 deals on record (13 secondary share transfers, 4 funding rounds, 1 rights issue), with disclosed funding of ₹6.79 Cr; the latest was in October 2022.
Deals on record (5 of 19)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Oct 2022 | IPO | ₹35.34 Cr | Investors: IPO - Trident Lifeline Limited, NAV Capital VCC- NAV Capital Emerging Star Fund, Bijal Mukesh Shah Huf, an individual |
| Dec 2016 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: Trident Texofab Limited |
| Dec 2016 | Rights issue | ₹1.2 Cr | Investors: Trident Texofab Limited , 3 individuals |
| Mar 2016 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: Trident Texofab Limited , 2 individuals |
| Mar 2014 | Secondary share transfer | Undisclosed | Buyer: Trident Texofab Limited Seller: an individual |
Full deal history
All 19 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Trident Lifeline Limited
Trident Lifeline Limited has 1 court case on record: 1 where it is another party. All case is pending. Status as checked on 04 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 1 | 0 | 1 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Gujarat | Special civil application | Company is another party | Pending |
Full case history
All 1 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Trident Lifeline Limited
Trident Lifeline Limited has 13 MSME Form 1 returns on record between 2019 and 2023, listing 435 overdue payments to 43 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 43)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Shreeji Sharan Pharmapack LLP | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 13 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Trident Lifeline Limited
Trident Lifeline operates one associated brand: Trident Lifeline. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of liquid orals, topical preparations, capsule, and other drugs | tridentlifeline.com |
Employees and EPFO Compliance at Trident Lifeline Limited
Trident Lifeline Limited has a workforce of 27 employees as of Apr 07, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Group Structure of Trident Lifeline Limited
Trident Lifeline has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares Held |
|---|---|---|
| Tns Pharma Private Limited | U24290GJ2021PTC128263 | - |
Showing major subsidiaries. Total: 1.
CIN History of Trident Lifeline Limited
Trident Lifeline has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L51909GJ2014PLC078227, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L51909GJ2014PLC078227 | Current |
| U51909GJ2014PTC078227 | Previous |
| U51909GJ2014PLC078227 | Previous |
Recent Activity on Trident Lifeline Limited
Trident Lifeline Limited has 17 board changes on record since 2020: 12 appointments and 5 cessations. The latest: Sachin Bhandari was appointed as Additional Director on 13 Jun 2026.
33 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Trident Lifeline Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Trident Lifeline Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Trident Lifeline Limited
Trident Lifeline has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAECT8906D1ZG | Gujarat | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Trident Lifeline Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Trident Lifeline Limited
Trident Lifeline is an active public limited company based in Surat, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 09 January 2014 (12+ years old) and is registered under CIN L51909GJ2014PLC078227.
Trident Lifeline reported revenue of ₹129.02 Cr for FY 2025-26 (up 48.4% YoY) based on consolidated financials.
Trident Lifeline has 8 current directors:
- Shravan H Patel - Managing Director
- Rupaben Chetan Jariwala - Whole-Time Director
- Hardik Jigishkumar Desai - Director
- Ashish Anandsingh Bafna - Director
- Falguni Bhavesh Jariwala - Director
- Mishal Shailesh Patel - Director
- Smita Kiran Davda - Additional Director
- Sachin Bhandari - Additional Director
The GSTIN of Trident Lifeline is 24AAECT8906D1ZG, registered in Gujarat.
The CIN (Corporate Identification Number) of Trident Lifeline is L51909GJ2014PLC078227. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes, Trident Lifeline is a listed company.
Trident Lifeline has 1 court case on record. 1 is pending.
Trident Lifeline was incorporated on 09 January 2014, making it 12+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Trident Lifeline has 19 deals on record (13 secondary share transfers, 4 funding rounds, 1 rights issue), with disclosed funding of ₹6.79 Cr; the latest was in October 2022.
The peers of Trident Lifeline by revenue are Linux Life Sciences Private Limited, Lozen Pharma Private Limited, Sanctus Global Formulations Limited, Navyug Pharma- Chem Pvt. Ltd, Quantime World Private Limited and 5 more, all in the Pharma industry (Formulations).
Sachin Bhandari was appointed as Additional Director on 13 Jun 2026. Smita Kiran Davda was appointed as Additional Director on 13 Jun 2026. Maniya Hardik Desai ceased to be Director on 22 Nov 2025. Trident Lifeline has 17 board changes on record in total.
Trident Lifeline has 13 MSME Form 1 returns on record between 2019 and 2023, listing 435 overdue payments to 43 micro and small suppliers. The latest return was filed on 21 Oct 2023.